Friday, February 7, 2020 – Sunday, February 9, 2020
Eden Roc Miami
Miami Beach, FL 33140
Phone: 305-531-0000
Website: www.edenrochotelmiami.com

We are pleased to invite you to the upcoming 17th Annual Winter Lung Cancer Conference^®, which will offer you a world-class continuing medical education event for the treatment of patients with lung cancer. Based on the well-received format of expert overviews with dynamic Medical Crossfire^® exchanges, this meeting will provide you with the most cutting-edge research and practical information for the care of your patients, as well as offer a preview of new agents and techniques that will inform the future of lung cancer treatment.

This program, led by world-class thoracic oncologists, will offer you the chance to learn from and interact with international experts in several therapeutic areas, including immunotherapy, targeted agents, and multidisciplinary approaches. Throughout the program, question-and-answer sessions will provide the opportunity to consult with faculty and your community-based peers. Come to learn, but also to share your personal experiences and best practices in lung cancer management.

By participating in this exciting program, you will have the opportunity to learn state-of-the-art care, including:

• How to navigate the increasing options for immunotherapy-based regimens in metastatic disease
• How to utilize molecular testing at diagnosis and following progression on targeted therapies
• Approaches to selecting the best therapy for oncogene-driven NSCLC
• The use of consolidation immunotherapy in locally advanced disease
• Current approaches with surgery and radiation oncology in patients with thoracic malignancies

Be sure to join us for the 17th Annual Winter Lung Cancer Conference^® in Miami, Florida. We look forward to seeing you there!

This activity is supported by educational grants from AbbVie; AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 10.75 Contact Hours.

At the conclusion of this activity, you should be better prepared to:

• Integrate molecular testing strategies to inform treatment selection in patients with oncogene-driven NSCLC
• Evaluate emerging approaches for patient selection for immunotherapy and targeted agents
• Assess treatment strategies for early-stage and locally advanced lung cancer
• Describe the use of cytotoxic, targeted, and other systemic agents in the management of patients with lung cancer with or without oncogenic drivers
• Incorporate immunotherapeutic strategies in patients with thoracic malignancies along the disease continuum
• Discuss approaches to mitigate and manage treatment-related adverse events in patients with lung cancer

Rogerio C. Lilenbaum, MD
Director of Banner
MD Anderson Cancer Center
Phoenix, AZ

Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Member, Thoracic Oncology Program
Orlando, FL

Heather A. Wakelee, MD
Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Julie R. Brahmer, MD, MSc, FASCO
Director, Thoracic Oncology Program
Kimmel Cancer Center at Johns Hopkins Bayview
Professor of Oncology
Johns Hopkins Kimmel